Should GLP1 R agonist therapy be offered to women at high risk for breast cancer given recent data showing protective benefits?

Obese postmenopausal women are at higher risk for breast cancer (Xande & Giglio, PMID 40869064), and so it seems logical that weight loss will reduce risk. Reassuringly, glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications have not been shown to increase breast cancer risk (Mady et al., P...